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Background: Krüppel-like factor 4 (KLF4) is involved in many important cellular processes such as growth, development,
differentiation, proliferation, and apoptosis. The purpose of this study was to determine the significance of KLF4 in both
tumors and normal tissues of patients with colorectal cancer (CRC).
Methods: Between January 2003 and June 2005, 125 patients with CRC receiving treatment at the Yonsei Cancer Center
were selected. We examined the mRNA level of the KLF4 gene in primary CRC specimens and matched normal colon
tissues using real-time RT-PCR. Correlation of survival with clinicopathological parameters, including KLF4 level,
was investigated with univariate and multivariate analyses.
Results: CRC tissue had a significantly lower KLF4 level when compared with matched normal tissues (KLF4 in
tumors: 2007 ± 1531 copies/μl, KLF4 in normal tissues: 6586 ± 2834 copies/μl; P <0.0001). However, there was a
correlation between the KLF4 level in tumors and normal tissues. Patients with a high KLF4 level in matched
normal tissues were more likely than those with a low KLF4 level to develop recurrence and had poorer overall
survival (P = 0.005). Therefore, the KLF4 level in the normal tissue of individuals was associated with prognosis of
individuals.
Conclusions: Our data suggest that KLF4 mRNA expression level in normal tissues and tumors may be a useful
prognostic marker in patients with CRC.
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Worldwide, colorectal cancer (CRC) is the fourth most
commonly diagnosed cancer in men and third in women.
CRC is also the third most common cause of cancer-
related death [1]. Despite advances in diagnosis and treat-
ment of CRC, it remains a disease with high morbidity and
mortality. Assessment of prognosis through tumor node
metastasis (TNM) staging systems remains inappropriate
due to the considerable diversity and heterogeneity among
tissues of the same stage. Therefore, it is a necessary to
establish novel prognostic markers for cancer recurrence
and survival to improve treatment for individual patients.* Correspondence: SSJ338@yuhs.ac
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reproduction in any medium, provided the orKrüppel-like factors (KLFs) are a family of evolutio-
narily conserved mammalian zinc-finger transcription
factors named for their homology with Krüppel, a
Drosophila melanogaster protein [2]. It is now well
established that KLFs are involved in many important
cellular processes such as growth, development, diffe-
rentiation, proliferation, and apoptosis [3-5]. KLF4
(also called gut-enriched KLF or GKLF) was one of the
first KLF family members identified [6,7]. In addition
to regulating many important physiological processes,
KLF4 has been shown to play a role in pathologic condi-
tions such as cancer and inflammation [8-13]. More
recently, KLF4 was shown to play a crucial role in the
reprogramming of somatic cells into induced pluripotent
stem cells [10]. KLF4 is primarily expressed in postmitotic,
terminally differentiated epithelial cells and is stimulated
following p53-dependent DNA damage [14,15].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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pharyngeal squamous cell carcinoma [16,17], whereas its
expression in colorectal, gastric, and lung cancer is
reduced relative to normal tissues [13,18-22]. Thus, the
expression and role of KLF4 may vary according to
cancer location. Several studies have shown that KLF4
mRNA and protein expression is reduced in human
colorectal cancer [13,18,20,22]. Moreover, the level of
KLF4 expression is significantly decreased in familiar
and/or sporadic colonic adenomas and carcinomas when
compared with normal colonic tissues [13]. Taken together,
these findings suggest that downregulation of KLF4 protein
expression in the colon may contribute to cellular hyper-
proliferation and malignant transformation. Until recently,
the principal focus in cancer research has mostly been the
malignant cell itself. However, we now know that tumor
growth is not determined by malignant cells alone, but that
the tumor microenvironment has a major impact on cancer
growth, progression, and prognosis [23]. In this study, we
examined the KLF4 mRNA level in colorectal tumors and
normal tissues and evaluated the clinical significance of
KLF4 expression on prognosis in CRC patients.
Methods
Tissue samples
A total of 125 paraffin-fixed colorectal cancer and
matched normal tissue samples were obtained between
January 2003 and June 2005 from the Yonsei Cancer
Center, Severance Hospital (South Korea). All tumors and
matched normal tissues were obtained from surgical speci-
mens of patients with CRC. The matched normal tissues
were at least 2 cm away from the edge of corresponding tu-
mors. This study was approved by the Severance Hospital
Institutional Review Board, which waived the requirement
for informed consent.Figure 1 ROC curve. (A) ROC curve of tKLF4 (AUC 0.61). (B) ROC curve ofReal-time reverse transcription-polymerase chain
reaction analysis
Total RNA was isolated using the TRIzol™ method (Invitro-
gen, Carlsbad, California, United States), and first-strand
cDNA was synthesized with Moloney murine leukemia
virus reverse transcriptase (Promega, Madison, Wisconsin,
United States). Single-strand cDNA was used as a template
for subsequent PCR. Two microliters of cDNA from each
tissue were used for the real-time reverse transcription-
polymerase chain reaction (RT-PCR) assay. Templates were
amplified using QuantiTect SYBR Green PCR kit (QIA-
GEN, Valencia, California, United States). Primer (Proligo,
Singapore, Singapore) sequences used in RT-PCR were: 5'-
GGCAAAACCTACACAAAGAG-3' and 5'-GTAGTGCC
TGGTCAGTTCAT-3'. PCR was initiated at 95°C for 15 mi-
nutes to activate the HotstarTaq DNA polymerase (QIA-
GEN, Hilden, Germany), and then amplified for 35 cycles
at 95°C for 20 s, 50°C for 30 s, and 72°C for 45 s on a Rotor
Gene 2072D real-time PCR machine (Corbett Research,
New South Wales, Sydney, Australia). The amplified fluo-
rescence signal in each specimen was measured at the late
extension step of each cycle. To quantify each gene, 10-fold
dilution of human genomic DNA was used (Promega).
Data analysis
All statistical analyses were performed using SPSS for
Windows software, version 18.0 (SPSS Inc, Chicago,
Illinois, United States). We used a paired t-test to com-
pare the KLF4 level between tumors and matched normal
tissues. The tKLF4 (KLF4 level in tumors) cutoff level
was set to 2150 pg/dl (Area under the curve (AUC) 0.61,
sensitivity 60%, specificity 73%), and the nKLF4 (KLF4
level in normal tissues) cutoff level was set to 7969 pg/dl
(AUC 0.58, sensitivity 40%, specificity 65%) in a Receiver
operating characteritsitc (ROC) curve (Figure 1). ThenKLF4 (AUC 0.58).
Table 1 Patient characteristics
Number of patients (%)
Total patients 125
Age in years (median) 35-83 (62.0)
≤60 50 (40.0)
≥60 75 (60.0)
Sex
Male 82 (65.6)
Female 43 (34.4)
Positive nodes
absent 55 (44.0)
present 70 (56.0)
Stage
I 20 (16.0)
II 31 (24.8)
III 55 (44.0)
IV 19 (15.2)
Primary lesion
Right colon 24 (19.2)
Left colon 45 (36.0)
Rectum 56(44.8)
Histology
Well differentiated 16 (12.8)
Moderately differentiated 100 (80.0)
Poorly differentiated 5 (4.0)
Mucinous 4 (3.2)
Blood/lymphatic vessel invasion
Absent 109 (87.2)
Present 16 (12.8)
Surgery
Curative 113 (90.4)
Palliative 12 (9.6)
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cutoff levels. The χ2 test was applied to find the correlation
between the KLF4 level and clinicopathologic parameters.
A binary logistic model was used in the multivariate
analysis. Overall survival (OS) was measured from the date
of the CRC diagnosis to the date of death. Disease-free
survival (DFS) was defined as the time between the
diagnosis of CRC and recurrence of the disease. Survival
plots were estimated using the Kaplan-Meier method,
and differences in survival distributions were evaluated
using the log-rank test. In multivariate analysis, Cox
proportional hazards models were used to analyze the
effect of specified risk factors on OS. P < 0.05 was
considered to be statistically significant.
Results
Patient characteristics
Patient characteristics are shown in Table 1. The median
age of patients was 62 years (range 35 to 83 years), and
65.6% were male. On first diagnosis, 16.0% of the pa-
tients were stage I (n = 20), 24.8% were stage II (n = 31),
44.0% were stage III (n = 55), and 15.2% were stage IV
(n = 19). The anatomic site of the tumors was defined as
right colon (ascending colon cancer, transverse colon
cancer), left colon (descending colon cancer, sigmoid
colon cancer, rectosigmoid colon cancer), and rectum
(rectal cancer). Tumors were distributed with 19.2% (n =
24) on the right colon, 36.0% (n = 45) on the left colon, and
44.8% (n = 56) on the rectum. A median of 20 lymph nodes
(range 3 to 64) were taken and in only 12.8% (n = 16) of
patients, less than 12 lymph nodes were taken. In 56.0%
(n = 70) of patients, metastasis to the lymph nodes was
shown. Curative resection was performed in 90.4% (n =
113) of patients, and palliative surgery was performed in
9.6% (n = 12) of patients. Among patients with stage IV
(n = 19), 36.8% (n = 7) received curative resection (pri-
mary tumor resection and metastasectomy) and 63.2%
(n = 12) received palliative surgery. The median follow-
up period was 68.7 months (range 0.4 to 96.3 months),
and the median survival of surviving patients was
94.8 months (range 72.8 to 102.6 months). Thirty-five
patients died with a median survival of 29.8 months
(range 3.0 to 75.1 months), and the overall five-year
survival was 78.4% (98 out of 125).
Factors associated with KLF4 expression in normal and
tumor tissues
KLF4 mRNA expression levels were significantly decreased
in CRC tissues compared with matched normal tissues
(tKLF4: 2007 ± 1531 copies/μl, nKLF4: 6586 ± 2834 copies/
μl) (P <0.0001) (Figure 2). However, there was a correlation
between the nKLF4 and tKLF4 level (P <0.0001) (Figure 3).
In multivariate and univariate analysis, tKLF4 was signifi-
cantly associated with the tumor stage (univariate analysis:P = 0.031, multivariate analysis: P = 0.044) (Table 2). nKLF4
level had a significant relationship with age and anatomic
distribution in a multivariate logistic model that took into
account age, stage, gender, lymph nodes metastasis, and
anatomic distribution (P = 0.024, P = 0.046: right and left
colon, P = 0.027: right colon and rectum, respectively)
(Table 3). No significant differences were observed among
gender, differentiation, or lymph node status.Implication of KLF4 on survival
Figure 4 shows that OS was significantly poorer in pa-
tients with a high expression level of both nKLF4 and
tKLF4 (P = 0.036, P <0.0001, respectively). In multivari-
ate analysis, a higher level of nKLF4 (nKLF4 ≥ 7696) was
Figure 3 Correlation analysis of nKLF4 and tKLF4 expression.
(r2 = 0.349, P <0.0001).
Figure 2 KLF4 expression in CRC and matched normal tissues. (A) KLF4 mRNA expression levels were significantly decreased in CRC tissues
compared with matched normal tissues. (B) Bar graph of KLF4 mRNA expression levels.
Lee et al. World Journal of Surgical Oncology 2014, 12:232 Page 4 of 7
http://www.wjso.com/content/12/1/232an independent risk factor for survival (P = 0.005). Other
independent risk factors for survival were advanced
stage, lymph node metastasis, and poor differentiation.
In patients without distant metastases (stage I-III), those
with higher nKLF4 had decreased DFS and OS (P = 0.024,
P = 0.007, respectively) (Figure 5). In multivariate models
that included age, stage, lymph node status, and nKLF4,
only nKLF4 was a significant predictor for DFS (P = 0.023)
and OS (P = 0.011).
Discussion
Diverse molecular alterations are associated with the ini-
tiation and progression of CRC. The zinc-finger tran-
scription factor KLF4 is predominantly expressed in the
epithelial cells of the gastrointestinal tract and is an im-
portant regulator of intestinal epithelial cell homeostasis
and tumorigenesis [18,24,25]. In the few studies that
have analyzed the role of KLF4 as a prognostic marker
in CRC, a clear relationship has yet to emerge. A recent
study showed that loss of KLF4 was an independent
predictor of survival and disease recurrence, whereas an-
other study found that loss of KLF4 expression was not
associated with survival and disease recurrence [13,22].
In this study, we evaluated the level of KLF4 mRNA
expression level using real time RT-PCR in tumors and
matched normal tissues. Similar to previous studies, we
found a lower expression level of KLF4 in tumors than
in normal tissues. Additionally, we observed an elevated
KLF4 level in tumors from CRC patients with high KLF4
levels in matched normal tissues. The patients with high
KLF4 levels in normal tissues had shorter OS and DFS
than those with low KLF4 levels. Therefore, high KLF4
in the normal tissue of individuals appears to be associ-
ated with poor prognosis of those individuals with CRC.
A previous study showed that CRC patients who
lack KLF4 protein expression in tumors have a poorprognosis [22]. However in our study, patients with high
KLF4 mRNA expression in tumors had a worse progno-
sis than those with low KLF4. A few possibilities exist
that may explain this conflicting result. The first is that
the different methods used to measure KLF4 expression
may produce different results. We measured the level of
KLF4 mRNA using real-time RT-PCR, whereas the level
of KLF4 protein was detected by immunohistochemistry
in the other study [22]. The difference in protein and
mRNA expression levels suggests that KLF4 may be
regulated at multiple levels. The second possibility is
that CRC tissues contained not only tumor cells but also
other cells such as surrounding stromal cells. In such a
case, elevated KLF4 expression in surrounding stromal
cells, despite low KLF4 expression in the tumor cell
itself, would skew our analysis, leading us to incorrectly
Table 2 KLF4 expression in CRC and paired normal tissue
Variable tKLF4 P value* nKLF4 P value*
<2150 ≥2150 <7969 ≥7969
Age (years)
<60 36 (72.0%) 14 (28.0%) 42 (84.0%) 8 (16.0%)
≥60 44 (58.7%) 31 (41.3%) 0.128 51 (68.0%) 24 (32.0%) 0.045
Gender
Male 49 (60.5%) 32 (39.5%) 59 (72.8%) 22 (27.2%)
Female 31 (70.5%) 13 (29.5%) 0.268 34 (77.3%) 10 (22.7%) 0.588
Stage
I-III 72 (67.9%) 34 (32.1%) 79 (74.5%) 27 (25.5%)
IV 8 (42.1%) 11 (57.9%) 0.031 14 (73.7%) 5 (26.3%) 0.938
LN metastasis
+ 46 (64.8%) 25 (35.2%) 55 (77.5%) 16 (22.5%)
− 34 (63.0%) 20 (37.0%) 0.833 38 (70.4%) 16 (29.6%) 0.368
Anatomic distribution
Right 14 (58.3%) 10 (41.7%) 22 (91.7%) 2 (8.3%)
Left 33 (73.3%) 12 (26.7%) 32 (71.1%) 13 (28.9%)
Rectum 33 (58.9%) 23 (41.1%) 0.264 39 (69.9%) 17 (30.4%) 0.096
*P value estimated by Chi-square χ2 test.
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We are unaware of any other study that has analyzed the
association between KLF4 expression in normal tissues and
prognosis. Our study is the first to identify high KLF4
expression in normal tissues as an independent prognostic
marker for poor survival and disease recurrence.
Recent studies have revealed that hypermethylation of
the KLF4 5′-untranslated region and microRNA-146a
(miR-146a), miR-145, or miR-143 expression are associated
with altered KLF4 expression in human CRC tissue speci-
mens [18,26,27]. Further studies investigating hypermethy-
lation of the KLF4 5′-untranslated region and microRNA
expression will be important to determine how KLF4
expression is regulated in normal and tumor tissues. TheTable 3 Multivariate analysis of nKLF4 expression
Variable Estimated coefficient Estimated standard
Stage (I-III, IV) 0.108 0.611
Age in years (<60, ≥60) 1.087 0.482
Gender (M, F) −0.314 0.471
LN metastasis (+,−) 0.649 0.459
Anatomic distribution
(right, left colon)
1.644 0.826
Anatomic distribution
(right colon, rectum)
1.801 0.815
*P value estimated by binary logistic model including all available covariates.most striking aspect of our study is that KLF4 mRNA
expression level in normal tissues is an independent
predictor of OS and DFS. We identified a significant asso-
ciation between the KLF4 level in both tumor and normal
tissue and survival.Conclusions
Our data suggests that KLF4 mRNA expression level in
both normal and tumor tissue is a potential prognostic
marker in patients with CRC. Investigating how the
microenvironment influences KLF4 expression and thus
tumorigenesis, tumor progression, and prognosis, will be
important in future studies.error Wald X2
statistics
P value* Estimated
odds ratio
Confidence interval
for odds ratio
0.031 0.860 1.114 (0.336-3.685)
5.076 0.024 2.965 (1.152-7.631)
0.443 0.505 0.731 (0.290-1.840)
1.994 0.158 1.913 (0.778-4.705)
3.964 0.046 5.178 (1.026-26.135)
4.880 0.027 6.054 (1.225-29.916)
Figure 5 Kaplan-Meier disease-free survival (DFS) and overall survival (OS) curve of nKLF4 in stage I-III patients. (A) In patients without distant
metastases (stage I-III), those with higher nKLF4 had decreased DFS (P= 0.024). (B) In patients without distant metastases (stage I-III), those with higher
nKLF4 had decreased OS (P= 0.007).
Figure 4 Kaplan-Meier overall survival (OS) curve of nKLF4 and tKLF4 expression in all patients. (A) OS was significantly poorer in
patients with high expression level of both nKLF4 (P = 0.036). (B) OS was significantly poorer in patients with high expression level of both
tKLF4 (P < 0.0001).
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